Qualigen Therapeutics (NASDAQ:AIXC) Releases Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) issued its earnings results on Tuesday. The company reported ($0.79) EPS for the quarter, FiscalAI reports.

Qualigen Therapeutics Trading Up 0.7%

AIXC stock traded up $0.01 during mid-day trading on Thursday, reaching $1.35. 18,359 shares of the company’s stock were exchanged, compared to its average volume of 63,859. The firm has a market capitalization of $27.32 million, a P/E ratio of -0.18 and a beta of 0.52. The firm has a 50 day moving average of $1.30. Qualigen Therapeutics has a 12-month low of $0.92 and a 12-month high of $8.81.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Qualigen Therapeutics presently has a consensus rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.